Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis

Abstract Views: 1918
PDF: 767
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Several studies demonstrated the efficacy of the B-cell depletion therapy with rituximab (RTX) in RA patients, including those unresponsive to anti- TNF therapy, underlying the important role of B cells in this disease (1-5). Several recent papers have demonstrated a differential effects of RTX in depleting B-cells and blocking plasma cell generation at the synovial and at the bone marrow level (7-9). This differential effect may explain why among patients who respond to RTX, some relapse while others show a very prolonged response, independently from the reappearance of B-cells in the peripheral blood (6). However, the efficacy of RTX may also depend on the individual genetic predisposition. At this regard, very few data were produced by now.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Fabris, M., Quartuccio, L., Lombardi, S., Benucci, M., Manfredi, M., Saracco, M., Atzeni, F., Morassi, P., Cimmino, M., Pontarini, E., Fabro, C., Pellerito, R., Sarzi-Puttini, P., Cutolo, M., Carletto, A., Bambara, L., Fischetti, F., Curcio, F., Tonutti, E., & De VIta, S. (2010). Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo, 62(4), 253–258. https://doi.org/10.4081/reumatismo.2010.253